271 related articles for article (PubMed ID: 15609684)
1. [Effective treatment with rituximab in a patient with refractory idiopathic thrombocytopenic purpura].
Tanai C; Iki S; Nakahara F; Iijima K; Usuki K; Kuwana M; Urabe A
Rinsho Ketsueki; 2004 Nov; 45(11):1181-6. PubMed ID: 15609684
[TBL] [Abstract][Full Text] [Related]
2. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.
Cooper N; Stasi R; Cunningham-Rundles S; Feuerstein MA; Leonard JP; Amadori S; Bussel JB
Br J Haematol; 2004 Apr; 125(2):232-9. PubMed ID: 15059147
[TBL] [Abstract][Full Text] [Related]
5. [Idiopathic thrombocytopenic purpura associated with mantle cell lymphoma showing an increase in the platelet count receiving anti-CD20 antibody rituximab].
Kawachi Y; Ide M; Uchida T; Setsu K
Rinsho Ketsueki; 2003 Jan; 44(1):31-3. PubMed ID: 12649836
[TBL] [Abstract][Full Text] [Related]
6. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura.
Zhou Z; Yang R
Crit Rev Oncol Hematol; 2008 Jan; 65(1):21-31. PubMed ID: 17681784
[TBL] [Abstract][Full Text] [Related]
7. Rituximab in the treatment of relapsing idiopathic thrombocytopenic purpura.
Riksen NP; Keuning JJ; Vreugdenhil G
Neth J Med; 2003 Jul; 61(7):262-5. PubMed ID: 14567524
[TBL] [Abstract][Full Text] [Related]
8. Chronic refractory idiopathic thrombocytopenic purpura (ITP) and anti-CD20 monoclonal antibody: a case report.
Latifzadeh SZ; Entezari V
Clin Appl Thromb Hemost; 2006 Oct; 12(4):489-92. PubMed ID: 17000895
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.
Peñalver FJ; Jiménez-Yuste V; Almagro M; Alvarez-Larrán A; Rodríguez L; Casado M; Gallur L; Giraldo P; Hernández R; Menor D; Rodríguez MJ; Caballero D; González R; Mayans J; Millán I; Cabrera JR;
Ann Hematol; 2006 Jun; 85(6):400-6. PubMed ID: 16550390
[TBL] [Abstract][Full Text] [Related]
10. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
Schweizer C; Reu FJ; Ho AD; Hensel M
Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
[TBL] [Abstract][Full Text] [Related]
11. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia.
Saleh MN; Gutheil J; Moore M; Bunch PW; Butler J; Kunkel L; Grillo-López AJ; LoBuglio AF
Semin Oncol; 2000 Dec; 27(6 Suppl 12):99-103. PubMed ID: 11226008
[TBL] [Abstract][Full Text] [Related]
12. Partial response to anti-CD20 monoclonal antibody treatment of severe immune thrombocytopenic purpura in a patient with common variable immunodeficiency.
Carbone J; Escudero A; Mayayo M; Ballesteros M; Perez-Corral A; Sanchez-Ramon S; Sarmiento E; Micheloud D; Fernandez-Cruz E
Ann N Y Acad Sci; 2005 Jun; 1051():666-71. PubMed ID: 16127007
[TBL] [Abstract][Full Text] [Related]
13. [Rituximab treatment for adults with steroid-resistant idiopathic thrombocytopenic purpura].
Wang W; Yu QH; Zhang HY; Chu XX; Chen F; Zhang CQ; Zhou YH; Hou M
Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):225-7. PubMed ID: 18785508
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature.
Santos ES; Arosemena LR; Raez LE; O'Brien C; Regev A
Liver Int; 2006 Jun; 26(5):625-9. PubMed ID: 16762009
[TBL] [Abstract][Full Text] [Related]
15. Treatment of a patient with chronic immune thrombocytopenic purpura with rituximab and monitoring by flow cytometric analysis.
Thude H; Gruhn B; Werner U; Schorner U; Häfer R; Zintl F; Barz D
Acta Haematol; 2004; 111(4):221-4. PubMed ID: 15153715
[TBL] [Abstract][Full Text] [Related]
16. Clinical remission following monoclonal anti-CD20 therapy in two children with chronic refractory idiopathic thrombocytopenic purpura.
Moschovi M; Trimis G; Pergantou H; Platokouki H; Vrachnou E; Tzortzatou-Stathopoulou F
J Paediatr Child Health; 2005 Jul; 41(7):384-6. PubMed ID: 16014149
[TBL] [Abstract][Full Text] [Related]
17. Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura.
Bengtson KL; Skinner MA; Ware RE
J Pediatr; 2003 Nov; 143(5):670-3. PubMed ID: 14615744
[TBL] [Abstract][Full Text] [Related]
18. The role of autoantibody-producing plasma cells in immune thrombocytopenic purpura refractory to rituximab.
Kuwana M; Iki S; Urabe A
Am J Hematol; 2007 Sep; 82(9):846-8. PubMed ID: 17506067
[TBL] [Abstract][Full Text] [Related]
19. Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura.
Aggarwal A; Catlett JP
South Med J; 2002 Oct; 95(10):1209-12. PubMed ID: 12425512
[TBL] [Abstract][Full Text] [Related]
20. [Clinical study of standard dose of rituximab for the treatment of refractory primary immune thrombocytopenia].
Zhu YC; Wang W; Zhou YH; Wang XM; Wang X; Wang YL; Sun GZ; Hou M
Zhonghua Xue Ye Xue Za Zhi; 2011 Mar; 32(3):163-7. PubMed ID: 21535953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]